Study guide
5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols
NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacist Licensure & Reciprocity
1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement
2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios
2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles
3 Chapter 3: Prescriptive Authority & Practitioner Categories
3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members
4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)
4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR
5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling
6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)
7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose
7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)
8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping
8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)
9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety
9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment
12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy
12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols
5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols
Key Takeaways Explain This Topic AI
Pharmacists must complete an ACPE-accredited immunization training course of at least 20 hours with live injection assessment and maintain active BLS/CPR certification for healthcare providers.
The PREP Act expanded pharmacist authority nationwide to administer ACIP-recommended pediatric vaccines (ages 3–18) and COVID-19/flu vaccines under federal preemption.
Emergency response protocols require immediate administration of intramuscular epinephrine (0.3 mg for adults, 0.15 mg for pediatric patients) for anaphylaxis, followed by calling 911.
Federal law mandates providing the current Vaccine Information Statement (VIS) to the patient or caregiver prior to administering any vaccine.
Pharmacists must report all administered vaccines to the state Immunization Information System (IIS) registry within state-specified timeframes (typically within 14 days or 72 hours) and report adverse events to VAERS.
Last updated: July 2026
5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols
MPJE Core Concept: Pharmacist immunization authority is established through state pharmacy practice acts, statewide protocol agreements, standing orders, and federal provisions under the Public Readiness and Emergency Preparedness (PREP) Act. Pharmacists must complete rigorous ACPE-accredited training, maintain active Healthcare Provider BLS/CPR certification, adhere to strict age thresholds, provide mandatory Vaccine Information Statements (VIS), report to state Immunization Information Systems (IIS) within mandated windows (typically within 14 days), and report adverse events to VAERS.
1. Statutory & Regulatory Foundations of Immunization Authority
Pharmacists serve as primary vaccine administrators across the United States. Authority to administer vaccines stems from three distinct legal mechanisms:
State-Specific Immunization Protocols & Standing Orders: Issued by a state health officer or collaborating physician, authorizing pharmacists to administer specified vaccines to defined age groups without individual prescriptions.
Individual Patient Prescriptions: Specific orders written by a licensed prescriber for an individual patient.
Federal PREP Act Preemption: The Public Readiness and Emergency Preparedness (PREP) Act and its amendments expanded pharmacist, pharmacy intern, and qualified pharmacy technician authority nationwide to administer ACIP-recommended pediatric vaccines (ages 3–18) and COVID-19/seasonal influenza vaccines, preempting more restrictive state laws during designated public health emergencies and ongoing PREP Act coverage windows.
2. Qualification, Training, and Certification Requirements
To lawfully administer vaccines, pharmacists (and supervising interns) must satisfy specific statutory credentialing criteria:
Credential / Requirement Statutory Standard & Implementation Details
ACPE-Accredited Training Course Completion of a minimum 20-hour ACPE-accredited immunization training program incorporating didactic study, hands-on injection technique, intramuscular (IM) and subcutaneous (SC) administration assessment, and emergency response management.
BLS/CPR Certification Maintenance of active Basic Life Support (BLS) / CPR certification for healthcare providers (must include hands-on practical skills evaluation; purely online CPR courses do not satisfy board requirements).
Continuing Pharmacy Education (CPE) Completion of state-mandated immunization-specific CPE hours (typically 1 to 2 hours per licensure renewal cycle ) covering vaccine storage, ACIP updates, or safety.
Emergency Anaphylaxis Protocol Mandatory completion of training in recognizing acute systemic anaphylaxis and immediate administration of intramuscular epinephrine and diphenhydramine.
3. Protocol Architecture, Age Restrictions, & Vaccine Types
State laws establish specific age thresholds and protocol structures governing pharmacist administration of vaccines.
Vaccine Category Standard Age Thresholds (State Law vs. PREP Act) Protocol Requirements IIS Registry Reporting Window
Seasonal Influenza Adults and pediatrics (Down to age 3+ under PREP Act; state laws vary from 3+ to 9+ without prescription). Standing order or statewide protocol. Within 14 days (or state-specified window e.g., 24-72 hours).
ACIP Routine Pediatric Vaccines (e.g., MMR, Varicella, DTaP, HPV, IPV) Ages 3 through 18 under PREP Act; state laws may require individual prescription for younger children (e.g., under 7 or 13). Federal PREP Act protocol or state standing order. Mandatory state IIS reporting within 14 days .
Adult ACIP Routine Vaccines (e.g., Pneumococcal, Shingrix, Tdap, Hepatitis A/B) Age 18+ (or 14+ in many state protocols). Statewide protocol or collaborative standing order. Mandatory state IIS reporting within 14 days .
Travel Vaccines (e.g., Yellow Fever, Typhoid, Japanese Encephalitis) Age 18+ (often restricted; Yellow Fever requires certified site designation). Specific physician CPA or specialized standing order. Mandatory state IIS reporting within 14 days .
4. Pre-Administration Protocols & Vaccine Information Statements (VIS)
Federal law under the National Childhood Vaccine Injury Act (NCVIA) mandates specific pre-administration disclosures:
Mandatory VIS Delivery: Prior to administering any vaccine covered under the NCVIA (e.g., Influenza, MMR, Varicella, Tdap, HPV, Pneumococcal), the pharmacist must provide the most current edition of the Vaccine Information Statement (VIS) produced by the CDC to the patient or legal guardian.
Timing of VIS: The VIS must be delivered before administration, allowing adequate time for the patient or guardian to read the document and ask questions.
Documentation of VIS: The pharmacy record must document the specific edition date of the VIS provided, the date the VIS was supplied, and the date of vaccine administration.
5. Emergency Anaphylaxis Management Protocols
Pharmacists administering vaccines must maintain an immediate, accessible emergency anaphylaxis kit containing epinephrine and supportive supplies.
Acute Reaction Primary Medication Adult Dosage & Route Pediatric Dosage & Route Action Protocol
Systemic Anaphylaxis (Bronchospasm, airway edema, hypotension, diffuse urticaria) Epinephrine (1 mg/mL / 1:1000 solution or autoinjector) 0.3 mg IM into anterolateral thigh. May repeat every 5–15 minutes up to 3 doses if EMS is delayed. 0.15 mg IM (for patients 15–30 kg) into anterolateral thigh. Call 911 immediately. Place patient supine, monitor vitals, administer CPR if cardiac arrest occurs.
Localized Mild Urticaria / Pruritus Diphenhydramine (Oral or IM) 25 mg to 50 mg PO or IM. 1 mg/kg (max 25 mg) PO or IM. Monitor closely for progression to systemic anaphylaxis.
- 6. Recordkeeping, Registry Reporting, & Cold-Chain Storage
- Immunization Registry (IIS) & VAERS Reporting
State IIS Registry Reporting: State pharmacy acts require pharmacists to report all administered immunizations to the state Immunization Information System (IIS) registry within a specified timeframe—most commonly within 14 days (or shorter windows such as 24 to 72 hours in select jurisdictions).
Physician Notification: Pharmacists must notify the patient's primary care physician (if identified) within state-mandated timeframes (typically 14 days).
VAERS Reporting: Under federal law, pharmacists must report any clinically significant adverse event, vaccine administration error, or unexpected complication following immunization to the Vaccine Adverse Event Reporting System (VAERS) .
Cold-Chain Storage and Temperature Monitoring
Refrigerated Vaccines: Maintained between 2°C and 8°C (36°F to 46°F) .
Frozen Vaccines (e.g., Varicella, MMRV): Maintained between -50°C and -15°C (-58°F to 5°F) .
Ultra-Cold mRNA Vaccines: Maintained between -90°C and -60°C (-130°F to -76°F) .
Temperature Monitoring Equipment: Pharmacies must utilize a Digital Data Logger (DDL) with a detachable buffered probe in each storage unit. Temperature logs must be reviewed and recorded twice daily. Temperature excursion records must be retained for at least 2 to 3 years .